Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, by Disease Type (Hepatitis, Alcohol Induced Liver Disease, Liver Cancer, Fatty Liver Disease, and Others), by Drug Class (Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobuli

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, by Disease Type (Hepatitis, Alcohol Induced Liver Disease, Liver Cancer, Fatty Liver Disease, and Others), by Drug Class (Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobulin, and Others), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country (Turkey, Saudi Arabia, Israel, UAE, Egypt, and Rest of Middle East and Turkey) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Chronic liver disease is associated with the progressive destruction of liver parenchyma for longer period of time (6 months) leading to liver fibrosis and cirrhosis. The main etiology of CLD include alcohol induced liver, hepatitis virus (B, C, and D), hepatocellular carcinoma (HCC), liver cancer, and fatty liver diseases. The treatment for chronic liver diseases include chemotherapy, targeted therapy, vaccines, immunoglobulin, and others. Market players such as IceCure Medical, BioLineRx Ltd., Oramed Pharmaceuticals Inc., and BioLineRx Ltd. are engaged in the development of novel treatment options for CLD.
Middle East and Turkey chronic liver disease therapeutics market is estimated to be valued at US$ 1,015 Mn in 2021 and is expected to reach US$ 1,500 Mn by 2028, exhibiting a CAGR of 5.8% during the forecast period (2021-2028).
Market Dynamics
The increasing incidence of liver disease, growing geriatric population, Government and non-government awareness programs related to liver disease, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Middle East and Turkey chronic liver disease therapeutics market over the forecast period.
According to National Library of Medicine, in the Middle East, the prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing, with associated risk factors including Obesity, and type 2 Diabetes. The patient’s progress to develop Nonalcoholic Steatohepatitis (NASH) is about 20% to 30%. Younossi, a nationally recognized leader specializing in hepatology and gastroenterology, reported that in Middle East the prevalence to be highest (33%) in a meta-analysis on Global Epidemiology of NAFLD. Awareness with suspected NAFLD has increased over last two decades, but 95% of the patients are still unaware about having liver disease.
Key features of the study:
This report provides an in-depth analysis of the Middle East and Turkey chronic liver Disease (CLD) therapeutics market, provides market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Middle East and Turkey chronic liver disease (CLD) therapeutics market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc., and Pfizer Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
Middle East and Turkey chronic liver disease (CLD) therapeutics market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Turkey chronic liver disease (CLD) therapeutics market
Detailed Segmentation:
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Disease Type:
Hepatitis
Alcohol Induced Liver Disease
Liver Cancer
Fatty Liver Disease
Others
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Drug Class:
Chemotherapy Drugs
Targeted therapy
Vaccines
Immunoglobulin
Others
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Route of Administration:
Oral
Parenteral
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, By Country:
Middle East
By Country:
Turkey
By Disease Type:
Hepatitis
Alcohol Induced Liver Disease
Liver Cancer
Fatty Liver Disease
Others
By Drug Class
Chemotherapy Drugs
Targeted therapy
Vaccines
Immunoglobulin
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Saudi Arabia
By Disease Type:
Hepatitis
Alcohol Induced Liver Disease
Liver Cancer
Fatty Liver Disease
Others
By Drug Class
Chemotherapy Drugs
Targeted therapy
Vaccines
Immunoglobulin
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Israel
By Disease Type:
Hepatitis
Alcohol Induced Liver Disease
Liver Cancer
Fatty Liver Disease
Others
By Drug Class
Chemotherapy Drugs
Targeted therapy
Vaccines
Immunoglobulin
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
UAE
By Disease Type:
Hepatitis
Alcohol Induced Liver Disease
Liver Cancer
Fatty Liver Disease
Others
By Drug Class
Chemotherapy Drugs
Targeted therapy
Vaccines
Immunoglobulin
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Egypt
By Disease Type:
Hepatitis
Alcohol Induced Liver Disease
Liver Cancer
Fatty Liver Disease
Others
By Drug Class
Chemotherapy Drugs
Targeted therapy
Vaccines
Immunoglobulin
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Middle East and Turkey
By Disease Type:
Hepatitis
Alcohol Induced Liver Disease
Liver Cancer
Fatty Liver Disease
Others
By Drug Class
Chemotherapy Drugs
Targeted therapy
Vaccines
Immunoglobulin
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Hoffmann-La Roche AG*
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Swedish Orphan Biovitrum AB
GlaxoSmithKline Plc
Sanofi S.A
Teva Pharmaceutical Industries Ltd
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
AbbVie Inc.
Abbott Laboratories
AstraZeneca plc.
Pfizer Inc.
“*” marked represents similar segmentation in other categories in the respective section.